Vascugen is dedicated to revolutionizing the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow, particularly for those patients at high risk for amputation and death for whom few to no treatment options remain. The company’s lead product is an allogeneic vasculogenic cell – a cell with the potential to forge new blood vessels in oxygen-starved tissues. The vasculogenic cell product is manufactured from induced pluripotent stem cells (iPSCs), which provide a limitless source from which to produce off-the-shelf, cryopreserved doses at scale.